Xcellerated T CellsTM in Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
This trial is a phase II, randomized study of patients with multiple myeloma. All patients
will receive Xcellerated T Cells, with or without prior fludarabine therapy.
15 patients in each study arm will be followed for 6 months.